Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
Mona MunteanuRaluca PaisValentina PetaOlivier DeckmynJoseph MoussalliYen NgoMarika RudlerPascal LebrayFrederic CharlotteVincent ThibaultOlivier LucidarmeAn NgoFrançoise Imbert-BismutChantal HoussetDominique ThabutVlad RatziuThierry Poynardnull nullPublished in: Alimentary pharmacology & therapeutics (2018)
The FibroTest has a high prognostic value in NAFLD for the prediction of liver-related death. (ClinicalTrials.gov number, NCT01927133).
Keyphrases